Item request has been placed!
×
Item request cannot be made.
×

Processing Request
Outcomes of Enterococcus faecalis infective endocarditis according to MIC of amoxicillin: a multicentric study
Item request has been placed!
×
Item request cannot be made.
×

Processing Request
- المؤلفون: Do Rego, Hermann; Kherabi, Yousra; Corvec, Stephane; Plouzeau-Jayle, Chloé; Bouchiat, Coralie; Macheda, Gabriel; Meyer, Sylvain; Cattoir, Vincent; Piau, Caroline; Guillard, Thomas; Zahar, Jean-Ralph; Farfour, Eric; Lecomte, Raphaël; Amara, Marlène; Isnard, Christophe; Le Monnier, Alban; Pilmis, Benoit
- المصدر:
EISSN: 2632-1823 ; JAC-Antimicrobial Resistance ; https://hal.inrae.fr/hal-04764203 ; JAC-Antimicrobial Resistance, 2024, 6 (6), ⟨10.1093/jacamr/dlae167⟩
- الموضوع:
- نوع التسجيلة:
article in journal/newspaper
- اللغة:
English
- معلومة اضافية
- Contributors:
AP-HP - Hôpital Bichat - Claude Bernard Paris; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP); Groupe Hospitalier Paris Saint-Joseph (hpsj); CIC Cochin Pasteur (CIC 1417); Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin AP-HP; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité); Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes); Immunology and New Concepts in ImmunoTherapy (INCIT); Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE); Nantes Université - pôle Santé; Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé; Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ); Centre hospitalier universitaire de Poitiers = Poitiers University Hospital (CHU de Poitiers La Milétrie ); Hospices Civils de Lyon (HCL); Service des Maladies Infectieuses et Tropicales CHRU Nancy; Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy); Anti-infectieux : supports moléculaires des résistances et innovations thérapeutiques (RESINFIT); CHU Limoges-Institut National de la Santé et de la Recherche Médicale (INSERM)-OmégaHealth (ΩHealth); Université de Limoges (UNILIM)-Université de Limoges (UNILIM); Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Pontchaillou; ARN régulateurs bactériens et médecine (BRM); Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes (Biosit : Biologie - Santé - Innovation Technologique); Centre Hospitalier Universitaire Rennes; Pathologies Pulmonaires et Plasticité Cellulaire - UMR-S 1250 (P3CELL); Université de Reims Champagne-Ardenne (URCA)-Institut National de la Santé et de la Recherche Médicale (INSERM); Laboratoire de Bactériologie-Virologie-Hygiène hospitalière CHU Reims; Hôpital universitaire Robert Debré Reims (CHU Reims); Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)); Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord; Hôpital Avicenne AP-HP; Hôpital Foch Suresnes; Service de Biologie CH Versailles; Centre Hospitalier de Versailles André Mignot (CHV); Dynamique Microbienne associée aux Infections Urinaires et Respiratoires (DYNAMICURE); Université de Caen Normandie (UNICAEN); Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN); Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM); Service de Microbiologie CHU Caen; Normandie Université (NU)-Normandie Université (NU)-CHU Caen; Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN); MICrobiologie de l'ALImentation au Service de la Santé (MICALIS); AgroParisTech-Université Paris-Saclay-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE); Université Paris-Saclay
- بيانات النشر:
CCSD
- الموضوع:
2024
- Collection:
Université de Limoges: HAL
- نبذة مختصرة :
International audience ; Abstract Background The incidence of Enterococcus faecalis infective endocarditis is increasing over time. Data on the impact of minimum inhibitory concentration (MIC) of amoxicillin on treatment outcomes are scarce. The objective of this study was to describe the epidemiology of E. faecalis infective endocarditis and to evaluate whether the MIC of amoxicillin might influence mortality. Materials We retrospectively included all consecutive patients diagnosed with definite E. faecalis infective endocarditis between 2013 and 2020 in 11 French hospitals. We extracted data from the local diagnosis-related group (DRG) database and matched these data with microbiological results. Amoxicillin MIC was determined by Etest strip. The primary endpoints were endocarditis-related mortality and risk factors for endocarditis-related mortality including amoxicillin MIC. Results A total of 403 patients with definite E. faecalis infective endocarditis were included. Patients were predominantly male (76.4%) with a median age of 74 years (67–82). Embolic complications occurred in 170 (42.1%) patients. Cardiac surgery was performed in 158 (61.5%) patients. The endocarditis-related mortality rate was 28.3% and the median delay between mortality and onset of hospitalization was 24 (9; 41) days. E. faecalis MIC of amoxicillin was available for 246 (61%) patients. The median MIC was 0.5 mg/L (0.4–0.7). Amoxicillin MIC was not found to be associated with in-hospital mortality. None of the variables included in the multivariate model were identified as a risk factor for mortality and there was no correlation between mortality and the duration of treatment for 4 weeks versus 6 weeks. Conclusions Higher amoxicillin MIC was not a risk factor leading to endocarditis-related mortality in definite E. faecalis infective endocarditis. However, further studies are needed to assess the effect of amoxicillin MIC on relapse.
- الرقم المعرف:
10.1093/jacamr/dlae167
- الدخول الالكتروني :
https://hal.inrae.fr/hal-04764203
https://hal.inrae.fr/hal-04764203v1/document
https://hal.inrae.fr/hal-04764203v1/file/dlae167.pdf
https://doi.org/10.1093/jacamr/dlae167
- Rights:
http://creativecommons.org/licenses/by-nc/ ; info:eu-repo/semantics/OpenAccess
- الرقم المعرف:
edsbas.116765A1
No Comments.